



The antibiotic crisis: Is there a role for traditional herbal remedies?

The ATAFUTI project: testing the antimicrobial potential of bearberries

Professor Michael Moore on behalf of the ATAFUTI trial team

Alternative Treatments for Adult Female Urinary Tract Infection: a double blind randomised controlled study.



What is the problem?

- 80% of antibiotics originate in primary care
- The majority are prescribed for self limiting conditions
 - Sore throats 60%
 - Acute bronchitis 60%
 - Urinary tract infection 93%

Potential strategies

- Improved communication skills
- Clinical scores
- Near patient tests
- Delayed prescribing
- Better symptom relief

Potential strategies

- Improved communication skills
- Clinical scores
- Near patient tests
- Delayed prescribing
- Better symptom relief

Urinary Tract Infections

- UTIs are common
- The symptoms associated with UTIs are distressing.
 (These usually settle without complications within 3 4 days but antibiotics do shorten the duration of symptoms)
- A delayed prescription strategy may help (It reduces antibiotic prescribing rates for respiratory infections)
- In UTI delayed strategy unlikely to be widely adopted without better symptom relief

Trial Objectives

Two candidates for **symptom relief** have been identified.

Ibuprofen Shown in one small study to provide good symptom relief

in UTI with only 33% of participants requiring antibiotics.

Known as bearberry, a herbal product which has been used •Uva Ursi.

as a traditional treatment for urine infections.

Primary objective: To compare whether ibuprofen or Uva Ursi

provide relief from urinary symptoms in adult

women with a suspected UTI.

Do ibuprofen or Uva Ursi result in Secondary objective

reduced antibiotic uptake



What is bear berry?



Arctostaphylos uvaursi

Dried Leaf









Trial Design

Factorial Design

- ➤ Uva ursi + ibuprofen
- Placebo + ibuprofen
- Uva ursi no ibuprofen
- Placebo no ibuprofen
- Five days of trial medication and a delayed prescription for antibiotics.
- Delay antibiotics if possible.
- Symptom diary for 2 weeks.
- Notes review will be carried out 3 months following recruitment to document return visits to surgery with a UTI.

Progress to date

| Timeline | Action |
|----------------|--|
| December 2010 | Application to SPCR |
| March 2011 | Outline application to SPCR- withdrawn due to non availability of uk product Uvacin |
| February 2012 | Herbal supplier identified funding application to SPCR |
| April 2012 | Funding approved! |
| March 2013 | No progress with herbal formulation Switch supplier new contracts |
| June 2013 | Manufacturer unable to source ibuprofen- switch to alternative supplier |
| May 2014 | Import of herb raw ingredients and production of herbal product commence stability testing |
| September 2014 | Stability testing results prepare investigator brochure and submit application to MHRA |



Progress to date

| Feb 2015 | MHRA approval |
|-------------|---|
| Feb 2015 | MHRA withdraw Manufacture (IMP) license from supplier of ibuprofen |
| Feb-March | Re-write protocol, materials, database- resubmit ethics and MHRA |
| April 2015 | Trial unable to complete in timeframe of contracts Re-application to SPCR for new funding |
| June 2015 | MHRA and ethics approval for modified protocol |
| July 2015 | SPCR re-funding approved |
| August 2015 | Study opens |

School for Primary Care Research



Progress to Date

- 4th Augusts 1st site opens
- 12th August first patient in trial
- 30th November 63 participants

- Target recruitment 328
- Need to recruit 45 participants a month to achieve target by end of May 2016

Future developments

- Pelargonium sidoides
- Andrographis paniculata





Any Questions?











The ATAFUTI study is funded by the National Institute for Health Research School for Primary Care Research (NIHR SPCR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health.

School for Primary Care Research





Include on last page of presentation

The [name of project] is funded by the National Institute for Health Research School for Primary Care Research (NIHR SPCR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

National Institute for Health Research